Senior Director, Clinical ScienceTakeda Development Center Americas, Inc.Cambridge, Massachusetts, United States
LB 01.1 - Safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia: Interim results from a phase 2, randomized, double-blind, placebo-controlled study
Sunday, June 23, 202409:30 – 09:45 ICT
